Mr Eazi's Zagadat Capital acquires 17.31 per cent stake in Intravenous Infusions PLC

Mr. Eazi's Zagadat Capital GH. Ltd secured a 17.31 per cent stake in Intravenous Infusions PLC on Monday, 18 May 2026, on the Ghana Alternative Exchange (GAX). The regulatory disclosure revealed that Zagadat Capital, with Oluwatosin "Mr Eazi" Ajibade as its Chief Investment Officer, acquired a total of 47,514,775 shares. This block represents a massive slice of the pharmaceutical company's total issued share capital base, which stands at 274,410,000 shares.

The acquisition was executed entirely through a series of open-market purchases on the floor of the GAX. Laurus Africa Securities acted as the licensed dealing member to broker the multi-million share trade. The move comes immediately after the publication of Intravenous Infusions PLC's 2025 annual report. The management of Zagadat Capital explained that the shares were accumulated as part of a deliberate, long-term investment strategy geared toward expanding the domestic healthcare supply chain. According to the firm, the capital injection reflects its firm belief in the commercial viability of local medicine production, adding that it views Intravenous Infusions PLC as an enterprise of immense structural importance to the West African healthcare ecosystem.

Zagadat Capital clarified that the equity purchase is not intended to trigger a corporate takeover or destabilise the current administrative control of the company. Instead, the firm emphasized that its entry into the share registry is intended to build a solid, supportive partnership capable of sustaining the manufacturer's long-term growth and maximizing value for all existing stakeholders. The formal notification was filed in strict compliance with the transparency provisions of the Securities Industry Act, 2016 (Act 929) and the statutory rules of the Ghana Stock